Moximed Series D Funding Raises $91M

Moximed, a manufacturer of knee implants, revealed today that it has completed a $91 million Series D preferred stock transaction. $61 million is included in the investment round, with the possibility of completing on up to $30 million more.

Based in Fremont, California The money will be used by Moximed to quicken the commercialisation of their Misha knee device in the United States. April saw the de novo clearance of Misha, an implanted shock absorber (ISA), for the management of medial knee osteoarthritis (OA).

Chris Gleason, President and Chief Executive Officer of Moximed stated: “This financing is validation of the significant market opportunity for the MISHA Knee System.”

He continued: “We are seeing tremendous interest from surgeons and patients, and we are excited to rapidly expand our commercial infrastructure to address evolving patient needs in this growing market.”